261 related articles for article (PubMed ID: 27193863)
1. Anti-Microtubule Drugs.
Florian S; Mitchison TJ
Methods Mol Biol; 2016; 1413():403-21. PubMed ID: 27193863
[TBL] [Abstract][Full Text] [Related]
2. Microtubule-binding natural products for cancer therapy.
Yue QX; Liu X; Guo DA
Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
[TBL] [Abstract][Full Text] [Related]
3. Microtubule dynamics as a target in oncology.
Risinger AL; Giles FJ; Mooberry SL
Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
5. Tubulins - the target for anticancer therapy.
Vindya NG; Sharma N; Yadav M; Ethiraj KR
Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
7. Probing the pore drug binding site of microtubules with fluorescent taxanes: evidence of two binding poses.
Barasoain I; García-Carril AM; Matesanz R; Maccari G; Trigili C; Mori M; Shi JZ; Fang WS; Andreu JM; Botta M; Díaz JF
Chem Biol; 2010 Mar; 17(3):243-53. PubMed ID: 20338516
[TBL] [Abstract][Full Text] [Related]
8. Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
Jain V; Jain B; Tiwari P; Saini J; Jain UK; Pandey RS; Kumar M; Katare OP; Chandra R; Madan J
Anticancer Drugs; 2013 Apr; 24(4):327-36. PubMed ID: 23411683
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
Jordan MA
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
[TBL] [Abstract][Full Text] [Related]
10. Discovery of small molecule inhibitors that interact with γ-tubulin.
Friesen DE; Barakat KH; Semenchenko V; Perez-Pineiro R; Fenske BW; Mane J; Wishart DS; Tuszynski JA
Chem Biol Drug Des; 2012 May; 79(5):639-52. PubMed ID: 22268380
[TBL] [Abstract][Full Text] [Related]
11. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
[TBL] [Abstract][Full Text] [Related]
12. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
13. Novel anti-tubulin cytotoxic agents for breast cancer.
Morris PG; Fornier MN
Expert Rev Anticancer Ther; 2009 Feb; 9(2):175-85. PubMed ID: 19192956
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects.
Churchill CD; Klobukowski M; Tuszynski JA
Chem Biol Drug Des; 2015 Nov; 86(5):1253-66. PubMed ID: 26032329
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.
Ducki S; Mackenzie G; Greedy B; Armitage S; Chabert JF; Bennett E; Nettles J; Snyder JP; Lawrence NJ
Bioorg Med Chem; 2009 Nov; 17(22):7711-22. PubMed ID: 19837594
[TBL] [Abstract][Full Text] [Related]
16. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
17. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
18. [Microtubule polymerization inhibitors].
Takahata T; Sato A; Saito K; Yamagata K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():162-6. PubMed ID: 25831744
[No Abstract] [Full Text] [Related]
19. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
20. Microtubule drugs: action, selectivity, and resistance across the kingdoms of life.
Dostál V; Libusová L
Protoplasma; 2014 Sep; 251(5):991-1005. PubMed ID: 24652407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
